HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022
November 21 2022 - 9:00AM
Heart Test Laboratories, Inc. d/b/a HeartSciences
(NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”),
a medical technology company focused on saving lives by making an
ECG (also known as an EKG) a far more valuable screening tool
through the use of AI, today announced that Andrew Simpson, Chief
Executive Officer of HeartSciences, will be participating at
the at the 11th Annual Benchmark Discovery One-on-One Investor
Conference which is being held on December 1, 2022, at the New York
Athletic Club in New York City.
Mr. Simpson will take part in one-on-one
meetings with institutional analysts and investors throughout the
conference. The conference offers emerging growth and dynamic
publicly traded companies access to institutional and individual
investors in a unique one-on-one format.
To schedule a one-on-one meeting with Mr.
Simpson you may submit your request online via the link provided
upon registration. To register for the conference,
please
visit https://www.benchmarkcompany.com/news-events/upcoming-events/the-11th-annual-discovery-one-on-one-investor-conference.
About The Benchmark Company
The Benchmark Company is an institutionally
focused, research driven, sales trading and investment banking
firm. We were founded in 1988 and are headquartered in New
York City. Our focus is on fostering the long-term success of
our corporate clients through raising capital, providing strategic
advisory services, generating insightful research, and developing
institutional sponsorship by leveraging the firm’s sales, trading
and equity research capabilities. For more information,
please visit https://www.benchmarkcompany.com.
About HeartSciences
Heart Test Laboratories, Inc. d/b/a
HeartSciences is a medical technology company focused on applying
innovative AI-based technology to an ECG (also known as an EKG) to
expand and improve an ECG’s clinical usefulness. Millions of ECGs
are performed every week and the Company’s objective is to improve
healthcare by making an ECG a far more valuable cardiac screening
tool, particularly in frontline or point-of-care clinical settings.
HeartSciences’ first product candidate for FDA clearance, the
MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that
is also designed to provide diagnostic information related to
cardiac dysfunction which has traditionally only been available
through the use of cardiac imaging. The MyoVista® also provides
conventional ECG information in the same test. The business model,
which involves the use of the MyoVista® device and consumables for
each test, is expected to be “razor-razorblade” as the electrodes
used with the MyoVista® are proprietary to HeartSciences, and new
electrodes are required for every test performed.For more
information, please visit: https://www.heartsciences.com.
Twitter: @HeartSciences
Safe Harbor StatementThis announcement
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These forward-looking statements are made
under the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995 and are relating to the Company's
future financial and operating performance. All statements, other
than statements of historical facts, included herein are
"forward-looking statements" including, among other things,
statements about HeartSciences’ beliefs and expectations. These
statements are based on current expectations, assumptions and
uncertainties involving judgments about, among other things, future
economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the Company's control. The
expectations reflected in these forward-looking statements involve
significant assumptions, risks and uncertainties, and these
expectations may prove to be incorrect. Investors should not place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Potential risks and
uncertainties include, but are not limited to, risks discussed in
HeartSciences’ filings with the U.S. Securities and Exchange
Commission at www.sec.gov. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.
For investor and media inquiries, please
contact:Investor Relations:Crescendo Communications, LLCPhone:
(212) 671-1021Email: HSCS@crescendo-ir.com
Company:Gene GephartPhone: +1-737-414-9213
(US)Email: investorrelations@heartsciences.com
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Apr 2023 to Apr 2024